嘗高美集團(08371.HK)預期中期收入同比減少約11%
格隆匯 10 月 22日丨嘗高美集團(08371.HK)公告,集團截至2020年9月30日止6個月未經審核簡明綜合業績初步審閲,預期集團將錄得:
(1)收入較截至2019年9月30日止6個月減少約11%;及(2)公司淨利潤及股東應占利潤錄得:(i)不包括建議由GEM轉往聯交所主板的相關上市費用,與去年同期比較,減少約11%;及(ii)若敝除香港政府因應對新型冠狀病毒COVID-19而發放的特別補貼及上市費用,減少約75%。
減少的主要原因是香港政府為防控新型冠狀病毒COVID-19的傳播採取了一系列限制社交距離措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.